We pioneer innovative cell immunotherapies with the goal to give cancer patients a new lease of life.

T Cell Therapy Treatment: How Does it Work?

Step 1: Blood Collection

Patient’s blood is collected at hospital site.

Step 2: Transportation & Handling

Collected blood is transported to Tessa’s central production facility or satellite labs.

Step 3: VST Initiation & Expansion

Patient’s white blood cells are isolated and the virus-specific T (VST) cell population are selectively activated & expanded.

Step 4: Chemotherapy

Coinciding with the VST production period, the patient receives chemotherapy.

Step 5: Infusion & Monitoring

Tessa ships the patient’s VSTs to the hospital site, where the investigational therapy is intravenously infused in the patient and carefully monitored for any adverse reactions.

Actual therapy treatment for patients varies with cancer indications

Target Indications Include:

Nasopharyngeal Cancer

Nasopharyngeal cancer (NPC) originates in the nasopharynx, an area at the upper part of the throat behind the nose. Approximately 92,5001 new cases of NPC are diagnosed worldwide each year with mortality of close to 55,0001. Although radiotherapy is the main avenue of treatment for early-stage NPC, 20-30% of patients are diagnosed at an advanced stage of disease and are not considered curable. NPC is strongly associated with Epstein-Barr Virus (EBV) infection, particularly in Asia, where close to 100% of NPC tumors are EBV-positive.

Cervical Cancer

Cervical cancer (CC) is a cancer that originates in the cervical tissue of the female reproductive tract. Approximately 560,0001 new cases of CC are diagnosed worldwide each year with mortality of close to 300,0001. Human papillomavirus (HPV) infection is frequently associated with CC and 70 – 80% of CC and may be HPV-positive. Surgery, chemotherapy and/or radiotherapy are often used to treat advanced CC.

Oropharyngeal Cancer

Oropharyngeal cancer (OPC) is a cancer that originates in the oropharynx, an area at the back of the mouth that connects to the esophagus. Approximately 154,0001 new cases of OPC are diagnosed worldwide each year with mortality of close to 100,0001. 70% of these cancers are HPV-positive. Chemotherapy/Radiotherapy and/or surgery may be used to treat OPC. As with CC, vaccines against HPV are unable to treat OPC patients who are already infected with the virus.

Epstein-Barr virus (EBV)-associated lymphomas

Malignant lymphomas are malignancies arising from lymphoid organs and tissues. Approximately 589,580 new cases of lymphoma were diagnosed worldwide with mortality of 274,891 in 20181. Oncogenic EBV is associated with various types of lymphoma, including post-transplant lymphoproliferative disease (PTLD), Hodgkin’s lymphoma (HL), Non-Hodgkin’s lymphoma (NHL) and NK/T cell lymphoma2. Standard treatments of advanced HL and NHL are chemotherapy, radiotherapy and targeted therapy, and recently, CAR-T cell therapy was approved for a type of NHL. PTLD currently has limited treatment options with anti-CD20 antibody as the standard treatment.

1. Globocan 2018,
2. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. Neparidze N, Lacy J,  Clin Adv Hematol Oncol. 2014 Jun;12(6):358-71.